Skip to main content
Annexon, Inc. logo

Annexon, Inc. — Investor Relations & Filings

Ticker · ANNX ISIN · US03589W1027 US Manufacturing
Filings indexed 468 across all filing types
Latest filing 2024-04-25 Annual Report
Country US United States of America
Listing US ANNX

About Annexon, Inc.

https://annexonbio.com/

Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of complement medicines. The company's therapeutic approach is centered on inhibiting C1q, the initiating molecule of the classical complement pathway. By blocking C1q at the start of this immune cascade, Annexon aims to prevent the inflammation and tissue damage that drive a range of diseases. Its pipeline is focused on developing treatments for classical complement-mediated disorders affecting the body, brain, and eye, which include autoimmune, neurodegenerative, and ophthalmic conditions.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2024-04-25 English
DEFA14A
Regulatory Filings
2024-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-25 English
SC 13G
Major Shareholding Notification
2024-04-22 English
Director's Dealing 2024
Director's Dealing
2024-04-10 English
424B5
Regulatory Filings
2024-04-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.